Cuspa

Company Overview

Snapshot

Founded in August 2019 by Yair Feld, Cuspa operates with 1–10 employees. The company has secured funding across two rounds from one investor, with NGT3 participating. In July 2024, Cuspa received a grant from the Israel Innovation Authority to advance its medical device development.

Business overview

Cuspa is a Health Tech & Life Sciences company focused on developing transcatheter treatments for aortic valve insufficiency (AI), a heart condition where the valve fails to close properly, leading to backward blood flow. Its core product, CUSPER, is an artificial cusp designed to be attached to the native valve cusp/leaflet using a nitinol grasper. This technology aims to preserve the functionality of a healthy aortic valve and prevent AI, serving the cardiology and cardiovascular medical device markets globally.

Strategic signal

Cuspa's grant from the Israel Innovation Authority in July 2024 signals strong governmental validation and support for its innovative medical device technology. This non-equity funding is crucial for advancing the company's pre-clinical studies and optimizing the performance of its CUSPER device, indicating a positive trajectory for its product development and potential market entry in the medical treatment and therapeutics sector.

Company Intelligence Q&A

What is Cuspa's primary focus?

Cuspa is developing an artificial cusp, called CUSPER, for the transcatheter treatment of aortic valve insufficiency (AI), a heart disorder characterized by improper valve closure.

When was Cuspa founded?

Cuspa was founded in August 2019 by Yair Feld.

Which investor participated in Cuspa's funding rounds?

NGT3 participated in Cuspa's funding rounds, including a seed round in March 2020.

What is the CUSPER device?

The CUSPER is an artificial cusp, connected to a nitinol grasper, designed to be attached to the native aortic valve cusp/leaflet to treat aortic valve insufficiency by preserving valve functionality.

Has Cuspa received any grants?

In July 2024, Cuspa secured a grant from the Israel Innovation Authority to support its medical device development.